Sage Journals: Discover world-class research

Abstract

Crigler–Najjar syndrome type I is caused by mutations of the uridine diphospho-glucuronosyl transferase 1A1 (UGT1A1) gene resulting in life-threatening increase of serum bilirubin. Life-long correction of hyperbilirubinemia was previously shown with intravenous injection of high doses of a helper-dependent adenoviral (HDAd) vector expressing UGT1A1 in the Gunn rat, the animal model of Crigler–Najjar syndrome. However, such high vector doses can activate an acute and potentially lethal inflammatory response with elevated serum interleukin-6 (IL-6). To overcome this obstacle, we investigated safety and efficacy of direct injections of low HDAd doses delivered directly into the liver parenchyma of Gunn rats. Direct hepatic injections performed by either laparotomy or ultrasound-guided percutaneous injections were compared with the same doses given by intravenous injections. A greater reduction of hyperbilirubinemia and increased conjugated bilirubin in bile were achieved with 1×10¹¹ vp/kg by direct liver injections compared with intravenous injections. In sharp contrast to intravenous injections, direct hepatic injections neither raised serum IL-6 nor resulted in thrombocytopenia. In conclusion, ultrasound-guided percutaneous injection of HDAd vectors into liver parenchyma resulted in improved hepatocyte transduction and reduced toxicity compared with systemic injections and is clinically attractive for liver-directed gene therapy of Crigler–Najjar syndrome.

Pastore and colleagues examine the safety and efficacy of direct hepatic injection compared with intravenous injection of helper-dependent adenoviral vector in Gunn rats. They find that compared with intravenous injection, direct liver injection results in improved hepatocyte transduction and reduced toxicity, including reduced hyperbilirubinemia and thrombocytopenia.

Get full access to this article

View all access options for this article.

References

Beale

E.G.

et al. 1992. Cell-specific expression of cytosolic phosphoenolpyruvate carboxykinase in transgenic mice. FASEB J., 6:3330–3337.

Brunetti-Pierri

, Lee

2005. Gene therapy for inborn errors of liver metabolism. Mol. Genet. Metab., 86:13–24.

Brunetti-Pierri

, Ng

2008. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther., 15:553–560.

Brunetti-Pierri

, Ng

2009. Progress towards liver and lung-directed gene therapy with helper-dependent adenoviral vectors. Curr. Gene Ther., 9:329–340.

Brunetti-Pierri

, Ng

2011. Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum. Mol. Genet., 20:R7–R13.

Brunetti-Pierri

et al. 2004. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther., 15:35–46.

Brunetti-Pierri

et al. 2005a. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum. Gene Ther., 16:811–820.

Brunetti-Pierri

et al. 2005b. Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol. Ther., 12:99–106.

Brunetti-Pierri

et al. 2006. Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum. Gene Ther., 17:391–404.

10.

Brunetti-Pierri

et al. 2007. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol. Ther., 15:732–740.

11.

Brunetti-Pierri

et al. 2012. Balloon catheter delivery of helper-dependent adenoviral vector results in sustained, therapeutic hFIX expression in rhesus macaques. Mol. Ther., 20:1863–1870.

12.

Brunetti-Pierri

et al. 2013. Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors. Hum. Gene Ther., 24:761–765.

13.

Chetboul

et al. 1999. Expression of biologically active atrial natriuretic factor following intrahepatic injection of a replication-defective adenoviral vector in dogs. Hum. Gene Ther., 10:281–290.

14.

Chowdhury

J.R.

et al. 1993. Gunn rat: a model for inherited deficiency of bilirubin glucuronidation. Adv. Vet. Sci. Comp. Med., 37:149–173.

15.

Crettaz

et al. 2006. Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. Hepatology, 44:623–632.

16.

Dimmock

et al. 2011. Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors. Hum. Gene Ther., 22:483–488.

17.

Fox

I.J.

et al. 1998. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N. Engl. J. Med., 338:1422–1426.

18.

Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press: Washington, DC.

19.

Mane

V.P.

et al. 2006. Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. Gene Ther., 13:1272–1280.

20.

Morral

et al. 2002. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum. Gene Ther., 13:143–154.

21.

Muruve

D.A.

et al. 1999. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther., 10:965–976.

22.

Nathwani

A.C.

et al. 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365:2357–2365.

23.

Nunes

F.A.

et al. 1999. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum. Gene Ther., 10:2515–2526.

24.

O'Neal

W.K.

et al. 1998. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. Hum. Gene Ther., 9:1587–1598.

25.

Palmer

D.J.

, Ng

2004. Physical and infectious titers of helper-dependent adenoviral vectors: a method of direct comparison to the adenovirus reference material. Mol. Ther., 10:792–798.

26.

Palmer

D.J.

, Ng

2005. Helper-dependent adenoviral vectors for gene therapy. Hum. Gene Ther., 16:1–16.

27.

Piccolo

et al. 2013. SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors. Mol. Ther., 21:767–774.

28.

Raper

S.E.

et al. 2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80:148–158.

29.

Seppen

et al. 2006. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol. Ther., 13:1085–1092.

30.

Spivak

, Carey

M.C.

1985. Reverse-phase h.p.l.c. separation, quantification and preparation of bilirubin and its conjugates from native bile. Quantitative analysis of the intact tetrapyrroles based on h.p.l.c. of their ethyl anthranilate azo derivatives. Biochem. J., 225:787–805.

31.

Strauss

K.A.

et al. 2006. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur. J. Pediatr., 165:306–319.

32.

Sung

M.W.

et al. 2001. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol. Ther., 4:182–191.

33.

Sung

M.W.

et al. 2002. Intratumoral delivery of adenovirus-mediated interleukin-12 gene in mice with metastatic cancer in the liver. Hum. Gene Ther., 13:731–743.

34.

Suzuki

et al. 2010. Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories. Hum. Gene Ther., 21:120–126.

35.

Zhang

et al. 2001. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther., 3:697–707.

Improved Efficacy and Reduced Toxicity by Ultrasound-Guided Intrahepatic Injections of Helper-Dependent Adenoviral Vector in Gunn Rats

Abstract

Get full access to this article

References